BioVie outlines Parkinson's disease approach focusing on neuroinflammation and insulin resistance; topline data for bezisterim trial expected by end of June

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week outlined its evolving approach to Parkinson’s disease, with CEO Cuong Do highlighting the company’s focus on neuroinflammation and insulin resistance as key drivers of the condition. Speaking to Proactive, Do explained that while Parkinson’s is commonly associated with dopamine deficiency and loss of muscle control, this represents only part of the disease mechanism. He said the company believes inflammation in the brain leads to insulin resistance, which in turn deprives neurons of the energy they need to function. Do described the process by noting that inflammation “acts like rust on that lock,” preventing insulin from enabling glucose uptake into cells. BioVie’s lead drug candidate, bezisterim, is designed to target these underlying mechanisms. According to Do, clinical data has shown that the therapy can reduce neuroinflammation and reverse insulin resistance. He added that this may restore energy flow to neurons and improve their function. The company has already generated encouraging results from an earlier clinical study in which bezisterim was used alongside levodopa, the current standard of care. In that trial, patients receiving the combination demonstrated improved muscle control compared to those treated with levodopa alone, providing what Do described as “human proof of concept.” BioVie is now advancing a second study evaluating bezisterim as a standalone treatment in patients at an earlier stage of Parkinson’s disease. The trial has enrolled 60 participants, randomized between placebo and treatment arms. The objective is to demonstrate improvements not only in motor symptoms but also in non-motor aspects such as sleep disturbances, anxiety, and depression. Do indicated that the trial is fully enrolled and that the company expects to report topline data before the end of June. This upcoming readout represents a key catalyst, as positive results could support the broader use of bezisterim across different stages of Parkinson’s disease. No Investment Advice The content on this Site is provided for information purposes only and does not constitute investment advice, a personal recommendation, an offer or solicitation to buy or sell securities, or any other regulated activity. It should not be relied upon as the basis for any investment decision. Before making any investment decision, you should: * Read the relevant prospectus, term sheet, subscription agreement, or other offering documentation in full * Consider whether the investment is suitable for your individual circumstances, financial position, and objectives * Seek independent advice from an appropriately qualified financial adviser Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise. You may not recover the amount you invest, and in some cases you may be required to pay more. In exchange for publishing services rendered by the Company on behalf of BioVie Inc named herein, including the promotion by the Company of BioVie Inc in...